THERAPEUTIC ANTIBODIES AGAINST OSTEOPONTIN
Therapeutic antibodies specific for osteopontin and methods of using them for treating osteopontin-associated disorders are provided. In particular, antibodies, or antigen-binding fragments thereof, that inhibit thrombin-cleavage of osteopontin or block the activity of thrombin cleavage fragments of...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | MYLES, Timothy LEUNG, Lawrence L. K MORSER, Michael J |
| description | Therapeutic antibodies specific for osteopontin and methods of using them for treating osteopontin-associated disorders are provided. In particular, antibodies, or antigen-binding fragments thereof, that inhibit thrombin-cleavage of osteopontin or block the activity of thrombin cleavage fragments of osteopontin are provided. Additionally, antibody conjugates and pharmaceutical compositions or formulations comprising the antibodies or antibody conjugates as well as kits including the antibodies, conjugates, or formulations are also provided.
L'invention concerne des anticorps thérapeutiques spécifiques de l'ostéopontine et des procédés d'utilisation de ceux-ci pour le traitement de troubles associés à l'ostéopontine. En particulier, l'invention concerne des anticorps, ou des fragments de liaison à l'antigène de ceux-ci, qui inhibent le clivage de la thrombine de l'ostéopontine ou bloquent l'activité de fragments de clivage de la thrombine de l'ostéopontine. De plus, l'invention concerne des conjugués d'anticorps et des compositions ou des formulations pharmaceutiques comprenant les anticorps ou les conjugués d'anticorps, ainsi que des kits comprenant les anticorps, les conjugués ou les formulations. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2021030209A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2021030209A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2021030209A13</originalsourceid><addsrcrecordid>eNrjZNAK8XANcgxwDQ3xdFZw9AvxdPJ38XQNVnB0d_T0Cw5R8A8OcfUP8AdK-PEwsKYl5hSn8kJpbgZlN9cQZw_d1IL8-NTigsTk1LzUkvhwfyMDI0MDYwMjA0tHQ2PiVAEABg8l0A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>THERAPEUTIC ANTIBODIES AGAINST OSTEOPONTIN</title><source>esp@cenet</source><creator>MYLES, Timothy ; LEUNG, Lawrence L. K ; MORSER, Michael J</creator><creatorcontrib>MYLES, Timothy ; LEUNG, Lawrence L. K ; MORSER, Michael J</creatorcontrib><description>Therapeutic antibodies specific for osteopontin and methods of using them for treating osteopontin-associated disorders are provided. In particular, antibodies, or antigen-binding fragments thereof, that inhibit thrombin-cleavage of osteopontin or block the activity of thrombin cleavage fragments of osteopontin are provided. Additionally, antibody conjugates and pharmaceutical compositions or formulations comprising the antibodies or antibody conjugates as well as kits including the antibodies, conjugates, or formulations are also provided.
L'invention concerne des anticorps thérapeutiques spécifiques de l'ostéopontine et des procédés d'utilisation de ceux-ci pour le traitement de troubles associés à l'ostéopontine. En particulier, l'invention concerne des anticorps, ou des fragments de liaison à l'antigène de ceux-ci, qui inhibent le clivage de la thrombine de l'ostéopontine ou bloquent l'activité de fragments de clivage de la thrombine de l'ostéopontine. De plus, l'invention concerne des conjugués d'anticorps et des compositions ou des formulations pharmaceutiques comprenant les anticorps ou les conjugués d'anticorps, ainsi que des kits comprenant les anticorps, les conjugués ou les formulations.</description><language>eng ; fre</language><subject>CHEMISTRY ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES</subject><creationdate>2021</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20210218&DB=EPODOC&CC=WO&NR=2021030209A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25562,76317</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20210218&DB=EPODOC&CC=WO&NR=2021030209A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>MYLES, Timothy</creatorcontrib><creatorcontrib>LEUNG, Lawrence L. K</creatorcontrib><creatorcontrib>MORSER, Michael J</creatorcontrib><title>THERAPEUTIC ANTIBODIES AGAINST OSTEOPONTIN</title><description>Therapeutic antibodies specific for osteopontin and methods of using them for treating osteopontin-associated disorders are provided. In particular, antibodies, or antigen-binding fragments thereof, that inhibit thrombin-cleavage of osteopontin or block the activity of thrombin cleavage fragments of osteopontin are provided. Additionally, antibody conjugates and pharmaceutical compositions or formulations comprising the antibodies or antibody conjugates as well as kits including the antibodies, conjugates, or formulations are also provided.
L'invention concerne des anticorps thérapeutiques spécifiques de l'ostéopontine et des procédés d'utilisation de ceux-ci pour le traitement de troubles associés à l'ostéopontine. En particulier, l'invention concerne des anticorps, ou des fragments de liaison à l'antigène de ceux-ci, qui inhibent le clivage de la thrombine de l'ostéopontine ou bloquent l'activité de fragments de clivage de la thrombine de l'ostéopontine. De plus, l'invention concerne des conjugués d'anticorps et des compositions ou des formulations pharmaceutiques comprenant les anticorps ou les conjugués d'anticorps, ainsi que des kits comprenant les anticorps, les conjugués ou les formulations.</description><subject>CHEMISTRY</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2021</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZNAK8XANcgxwDQ3xdFZw9AvxdPJ38XQNVnB0d_T0Cw5R8A8OcfUP8AdK-PEwsKYl5hSn8kJpbgZlN9cQZw_d1IL8-NTigsTk1LzUkvhwfyMDI0MDYwMjA0tHQ2PiVAEABg8l0A</recordid><startdate>20210218</startdate><enddate>20210218</enddate><creator>MYLES, Timothy</creator><creator>LEUNG, Lawrence L. K</creator><creator>MORSER, Michael J</creator><scope>EVB</scope></search><sort><creationdate>20210218</creationdate><title>THERAPEUTIC ANTIBODIES AGAINST OSTEOPONTIN</title><author>MYLES, Timothy ; LEUNG, Lawrence L. K ; MORSER, Michael J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2021030209A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2021</creationdate><topic>CHEMISTRY</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><toplevel>online_resources</toplevel><creatorcontrib>MYLES, Timothy</creatorcontrib><creatorcontrib>LEUNG, Lawrence L. K</creatorcontrib><creatorcontrib>MORSER, Michael J</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>MYLES, Timothy</au><au>LEUNG, Lawrence L. K</au><au>MORSER, Michael J</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>THERAPEUTIC ANTIBODIES AGAINST OSTEOPONTIN</title><date>2021-02-18</date><risdate>2021</risdate><abstract>Therapeutic antibodies specific for osteopontin and methods of using them for treating osteopontin-associated disorders are provided. In particular, antibodies, or antigen-binding fragments thereof, that inhibit thrombin-cleavage of osteopontin or block the activity of thrombin cleavage fragments of osteopontin are provided. Additionally, antibody conjugates and pharmaceutical compositions or formulations comprising the antibodies or antibody conjugates as well as kits including the antibodies, conjugates, or formulations are also provided.
L'invention concerne des anticorps thérapeutiques spécifiques de l'ostéopontine et des procédés d'utilisation de ceux-ci pour le traitement de troubles associés à l'ostéopontine. En particulier, l'invention concerne des anticorps, ou des fragments de liaison à l'antigène de ceux-ci, qui inhibent le clivage de la thrombine de l'ostéopontine ou bloquent l'activité de fragments de clivage de la thrombine de l'ostéopontine. De plus, l'invention concerne des conjugués d'anticorps et des compositions ou des formulations pharmaceutiques comprenant les anticorps ou les conjugués d'anticorps, ainsi que des kits comprenant les anticorps, les conjugués ou les formulations.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_WO2021030209A1 |
| source | esp@cenet |
| subjects | CHEMISTRY METALLURGY ORGANIC CHEMISTRY PEPTIDES |
| title | THERAPEUTIC ANTIBODIES AGAINST OSTEOPONTIN |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T15%3A39%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=MYLES,%20Timothy&rft.date=2021-02-18&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2021030209A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |